ACLY and neoplasm: ENO1 glycolytic activity is strongly associated with increased ATP citrate lyase expression in gliomas[14], thus ENO1 may act as a metabolic tumor promoter conferring a selective growth advantage onto ENO1-overexpressing tumor cells.